{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:39:02Z","timestamp":1793385542088,"version":"4.5.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-11949-0","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T17:50:03Z","timestamp":1753984203000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["RpoB mutation patterns in Rifampicin-resistant tuberculosis: a Jiangxi Province study, 2021\u20132023"],"prefix":"10.1038","volume":"15","author":[{"given":"Zhan Qiu","family":"Mao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi Long","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilie","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen Qiong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei Mei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling Shan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li Chao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling Hua","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui Qiong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"issue":"6","key":"11949_CR1","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.tim.2018.02.012","volume":"26","author":"A Koch","year":"2018","unstructured":"Koch, A. & Mizrahi, V. Mycobacterium tuberculosis. Trends Microbiol. 26 (6), 555\u2013556. https:\/\/doi.org\/10.1016\/j.tim.2018.02.012 (2018).","journal-title":"Trends Microbiol."},{"issue":"8","key":"11949_CR2","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.12998\/wjcc.v12.i8.1536","volume":"12","author":"AM Ali","year":"2024","unstructured":"Ali, A. M. et al. Primary gastroduodenal tuberculosis presenting as gastric outlet obstruction: A case report and review of literature. World J. Clin. Cases. 12 (8), 1536\u20131543. https:\/\/doi.org\/10.12998\/wjcc.v12.i8.1536 (2024).","journal-title":"World J. Clin. Cases"},{"key":"11949_CR3","unstructured":"Alzayer, Z. & Al Nasser, Y. Primary lung tuberculosis. In: StatPearls. Treasure Island (FL): (StatPearls Publishing, 2023)."},{"key":"11949_CR4","doi-asserted-by":"publisher","first-page":"944183","DOI":"10.3389\/fimmu.2022.944183","volume":"13","author":"K Negi","year":"2022","unstructured":"Negi, K., Bhaskar, A. & Dwivedi, V. P. Progressive Host-Directed strategies to potentiate BCG vaccination against tuberculosis. Front. Immunol. 13, 944183. https:\/\/doi.org\/10.3389\/fimmu.2022.944183 (2022). Published 2022 Jul 28.","journal-title":"Front. Immunol."},{"key":"11949_CR5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.foot.2018.07.005","volume":"37","author":"R Faroug","year":"2018","unstructured":"Faroug, R. et al. Diagnosis and treatment of tuberculosis of the foot and ankle-A literature review. Foot (Edinb). 37, 105\u2013112. https:\/\/doi.org\/10.1016\/j.foot.2018.07.005 (2018).","journal-title":"Foot (Edinb)"},{"issue":"1","key":"11949_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12992-019-0459-9","volume":"15","author":"FT Gyimah","year":"2019","unstructured":"GyimahFT & Dako-Gyeke, P. Perspectives on TB patients\u2019 care and support: a qualitative study conducted in Accra metropolis, Ghana. Global Health. 15 (1), 19. https:\/\/doi.org\/10.1186\/s12992-019-0459-9 (2019). Published 2019 Mar 5.","journal-title":"Global Health"},{"issue":"2","key":"11949_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ijmyco.2012.05.003","volume":"1","author":"LA Chaudhry","year":"2012","unstructured":"Chaudhry, L. A., Zamzami, M., Aldin, S. & Pazdirek, J. Clinical consequences of non-compliance with directly observed therapy short course (DOTS): story of a recurrent defaulter. Int. J. Mycobacteriol. 1 (2), 99\u2013103. https:\/\/doi.org\/10.1016\/j.ijmyco.2012.05.003 (2012).","journal-title":"Int. J. Mycobacteriol"},{"key":"11949_CR8","first-page":"50","volume":"11","author":"M Abebe","year":"2012","unstructured":"Abebe, M. et al. TB case detection: can we remain passive while the process is active? Pan Afr. Med. J. 11, 50 (2012).","journal-title":"Pan Afr. Med. J."},{"key":"11949_CR9","doi-asserted-by":"publisher","unstructured":"Salgueiro, V. C. et al. Extracellular vesicles in mycobacteria: new findings in biogenesis, host-pathogen interactions, and diagnostics. mBio Published Online April. 3 https:\/\/doi.org\/10.1128\/mbio.02552-23 (2024).","DOI":"10.1128\/mbio.02552-23"},{"key":"11949_CR10","doi-asserted-by":"publisher","unstructured":"da Costa, C. et al. Perspectives on development and advancement of new tuberculosis vaccines. Int. J. Infect. Dis. Published Online Febr. 26 https:\/\/doi.org\/10.1016\/j.ijid.2024.106987 (2024).","DOI":"10.1016\/j.ijid.2024.106987"},{"issue":"3","key":"11949_CR11","doi-asserted-by":"publisher","first-page":"e136222","DOI":"10.1172\/JCI136222","volume":"131","author":"WH Boom","year":"2021","unstructured":"Boom, W. H., Schaible, U. E. & Achkar, J. M. The knowns and unknowns of latent Mycobacterium tuberculosis infection. J. Clin. Invest. 131 (3), e136222. https:\/\/doi.org\/10.1172\/JCI136222 (2021).","journal-title":"J. Clin. Invest."},{"issue":"2","key":"11949_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/cid\/ciw778","volume":"64","author":"DM Lewinsohn","year":"2017","unstructured":"Lewinsohn, D. M. et al. Official American thoracic society\/infectious diseases society of america\/centers for disease control and prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin. Infect. Dis. 64 (2), 111\u2013115. https:\/\/doi.org\/10.1093\/cid\/ciw778 (2017).","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"11949_CR13","doi-asserted-by":"publisher","first-page":"2239940","DOI":"10.1080\/22221751.2023.2239940","volume":"12","author":"Q Yang","year":"2023","unstructured":"Yang, Q. et al. The interaction of macrophages and CD8 T cells in Bronchoalveolar lavage fluid is associated with latent tuberculosis infection. Emerg. Microbes Infect. 12 (2), 2239940. https:\/\/doi.org\/10.1080\/22221751.2023.2239940 (2023).","journal-title":"Emerg. Microbes Infect."},{"issue":"7","key":"11949_CR14","doi-asserted-by":"publisher","first-page":"499","DOI":"10.5588\/ijtld.23.0032","volume":"27","author":"P Escalante","year":"2023","unstructured":"Escalante, P. et al. New diagnostics for the spectrum of asymptomatic TB: from infection to subclinical disease. Int. J. Tuberc Lung Dis. 27 (7), 499\u2013505. https:\/\/doi.org\/10.5588\/ijtld.23.0032 (2023).","journal-title":"Int. J. Tuberc Lung Dis."},{"issue":"9","key":"11949_CR15","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.3390\/microorganisms11092191","volume":"11","author":"JR Ledesma","year":"2023","unstructured":"Ledesma, J. R. et al. Global-, Regional-, and national-level impacts of the COVID-19 pandemic on tuberculosis diagnoses, 2020\u20132021. Microorganisms 11 (9), 2191. https:\/\/doi.org\/10.3390\/microorganisms11092191 (2023). Published 2023 Aug 30.","journal-title":"Microorganisms"},{"issue":"1","key":"11949_CR16","doi-asserted-by":"publisher","first-page":"7530","DOI":"10.1038\/s41598-021-86869-w","volume":"11","author":"D Shaweno","year":"2021","unstructured":"Shaweno, D., Horton, K. C., Hayes, R. J. & Dodd, P. J. Assortative social mixing and sex disparities in tuberculosis burden. Sci. Rep. 11 (1), 7530. https:\/\/doi.org\/10.1038\/s41598-021-86869-w (2021). Published 2021 Apr 6.","journal-title":"Sci. Rep."},{"key":"11949_CR17","doi-asserted-by":"publisher","unstructured":"Kak, N. et al. Strategic priorities for TB control in Bangladesh, Indonesia, and the Philippines - comparative analysis of national TB prevalence surveys. BMC Public Health.  20(1) 560. Published 2020 Apr 25. (2020). https:\/\/doi.org\/10.1186\/s12889-020-08675-9","DOI":"10.1186\/s12889-020-08675-9"},{"key":"11949_CR18","doi-asserted-by":"publisher","first-page":"100144","DOI":"10.1016\/j.jctube.2020.100144","volume":"19","author":"R Subbaraman","year":"2020","unstructured":"Subbaraman, R., Jhaveri, T. & Nathavitharana, R. R. Closing gaps in the tuberculosis care cascade: an action-oriented research agenda. J. Clin. Tuberc Other Mycobact. Dis. 19, 100144. https:\/\/doi.org\/10.1016\/j.jctube.2020.100144 (2020). Published 2020 Jan 11.","journal-title":"J. Clin. Tuberc Other Mycobact. Dis."},{"key":"11949_CR19","doi-asserted-by":"publisher","unstructured":"Singh, V. Tuberculosis treatment-shortening. Drug discov today. Published Online March. 26 https:\/\/doi.org\/10.1016\/j.drudis.2024.103955 (2024).","DOI":"10.1016\/j.drudis.2024.103955"},{"key":"11949_CR20","doi-asserted-by":"publisher","first-page":"102266","DOI":"10.1016\/j.mib.2023.102266","volume":"72","author":"J Zhu","year":"2023","unstructured":"Zhu, J., Liu, Y. J. & Fortune, S. M. Spatiotemporal perspectives on tuberculosis chemotherapy. Curr. Opin. Microbiol. 72, 102266. https:\/\/doi.org\/10.1016\/j.mib.2023.102266 (2023).","journal-title":"Curr. Opin. Microbiol."},{"issue":"6","key":"11949_CR21","doi-asserted-by":"publisher","first-page":"e867","DOI":"10.1002\/iid3.867","volume":"11","author":"M Moradi","year":"2023","unstructured":"Moradi, M. et al. Liposomal delivery system\/adjuvant for tuberculosis vaccine. Immun. Inflamm. Dis. 11 (6), e867. https:\/\/doi.org\/10.1002\/iid3.867 (2023).","journal-title":"Immun. Inflamm. Dis."},{"issue":"6","key":"11949_CR22","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.3390\/ijms24065202","volume":"24","author":"SSR Alsayed","year":"2023","unstructured":"Alsayed, S. S. R., Gunosewoyo, H. & Tuberculosis Pathogenesis, current treatment regimens and new drug targets. Int. J. Mol. Sci. 24 (6), 5202. https:\/\/doi.org\/10.3390\/ijms24065202 (2023). Published 2023 Mar 8.","journal-title":"Int. J. Mol. Sci."},{"key":"11949_CR23","doi-asserted-by":"publisher","first-page":"645485","DOI":"10.3389\/fimmu.2021.645485","volume":"12","author":"S Fatima","year":"2021","unstructured":"Fatima, S., Bhaskar, A. & Dwivedi, V. P. Repurposing Immunomodulatory drugs to combat tuberculosis. Front. Immunol. 12, 645485. https:\/\/doi.org\/10.3389\/fimmu.2021.645485 (2021). Published 2021 Apr 13.","journal-title":"Front. Immunol."},{"key":"11949_CR24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.coph.2018.08.001","volume":"42","author":"J Libardo","year":"2018","unstructured":"Libardo, J., Boshoff, M. D. & Barry, H. I. 3 The present state of the tuberculosis drug development pipeline. Curr. Opin. Pharmacol. 42, 81\u201394. https:\/\/doi.org\/10.1016\/j.coph.2018.08.001 (2018).","journal-title":"Curr. Opin. Pharmacol."},{"issue":"1","key":"11949_CR25","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/S1473-3099(21)00403-5","volume":"22","author":"C Lange","year":"2022","unstructured":"Lange, C. et al. 100 years of Mycobacterium bovis Bacille Calmette-Gu\u00e9rin. Lancet Infect. Dis. 22 (1), e2\u2013e12. https:\/\/doi.org\/10.1016\/S1473-3099(21)00403-5 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"11949_CR26","unstructured":"Okafor, C. N., Rewane, A. & Momodu, I. I. Bacillus calmette Guerin. In: StatPearls. Treasure Island (FL): StatPearls Publishing; July 3, (2023)."},{"issue":"4","key":"11949_CR27","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/resp.13245","volume":"23","author":"B Zhu","year":"2018","unstructured":"Zhu, B., Dockrell, H. M., Ottenhoff, T. H. M., Evans, T. G. & Zhang, Y. Tuberculosis vaccines: opportunities and challenges. Respirology 23 (4), 359\u2013368. https:\/\/doi.org\/10.1111\/resp.13245 (2018).","journal-title":"Respirology"},{"key":"11949_CR28","doi-asserted-by":"publisher","unstructured":"Felker, I. & Trajman, A. Shorter regimens for multidrug-\/rifampicin-resistant TB. Int .J. Tuberc. Lung Dis.  27 (1) 3\u20134. (2023). https:\/\/doi.org\/10.5588\/ijtld.22.0537.","DOI":"10.5588\/ijtld.22.0537"},{"key":"11949_CR29","doi-asserted-by":"publisher","first-page":"103937","DOI":"10.1016\/j.meegid.2019.103937","volume":"74","author":"M Grobbelaar","year":"2019","unstructured":"Grobbelaar, M. et al. Evolution of rifampicin treatment for tuberculosis. Infect. Genet. Evol. 74, 103937. https:\/\/doi.org\/10.1016\/j.meegid.2019.103937 (2019).","journal-title":"Infect. Genet. Evol."},{"issue":"8006","key":"11949_CR30","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41586-024-07206-5","volume":"628","author":"KA Eckartt","year":"2024","unstructured":"Eckartt, K. A. et al. Compensatory evolution in NusG improves fitness of drug-resistant M. tuberculosis. Nature 628 (8006), 186\u2013194. https:\/\/doi.org\/10.1038\/s41586-024-07206-5 (2024).","journal-title":"Nature"},{"issue":"6","key":"11949_CR31","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/s0092-8674(01)00286-0","volume":"104","author":"EA Campbell","year":"2001","unstructured":"Campbell, E. A. et al. Structural mechanism for rifampicin Inhibition of bacterial Rna polymerase. Cell 104 (6), 901\u2013912. https:\/\/doi.org\/10.1016\/s0092-8674(01)00286-0 (2001).","journal-title":"Cell"},{"issue":"5","key":"11949_CR32","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1021\/acschembio.6b01133","volume":"12","author":"SS Walker","year":"2017","unstructured":"Walker, S. S. et al. Affinity Selection-Mass spectrometry identifies a novel antibacterial RNA polymerase inhibitor. ACS Chem. Biol. 12 (5), 1346\u20131352. https:\/\/doi.org\/10.1021\/acschembio.6b01133 (2017).","journal-title":"ACS Chem. Biol."},{"issue":"2","key":"11949_CR33","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.molcel.2017.03.001","volume":"66","author":"W Lin","year":"2017","unstructured":"Lin, W. et al. Structural basis of Mycobacterium tuberculosis transcription and transcription Inhibition. Mol. Cell. 66 (2), 169\u2013179e8. https:\/\/doi.org\/10.1016\/j.molcel.2017.03.001 (2017).","journal-title":"Mol. Cell."},{"issue":"6","key":"11949_CR34","doi-asserted-by":"publisher","first-page":"e00284","DOI":"10.1128\/AAC.00284-19","volume":"63","author":"PB Smith","year":"2019","unstructured":"Smith, P. B. et al. Rifampin pharmacokinetics and safety in preterm and term infants. Antimicrob. Agents Chemother. 63 (6), e00284\u2013e00219. https:\/\/doi.org\/10.1128\/AAC.00284-19 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"18","key":"11949_CR35","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1056\/NEJMe2104499","volume":"384","author":"EJ Rubin","year":"2021","unstructured":"Rubin, E. J. & Mizrahi, V. Shortening the short course of tuberculosis treatment. N Engl. J. Med. 384 (18), 1764\u20131765. https:\/\/doi.org\/10.1056\/NEJMe2104499 (2021).","journal-title":"N Engl. J. Med."},{"issue":"3","key":"11949_CR36","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3390\/antibiotics3030317","volume":"3","author":"JC Palomino","year":"2014","unstructured":"Palomino, J. C. & Martin, A. Drug resistance mechanisms in Mycobacterium tuberculosis. Antibiot. (Basel). 3 (3), 317\u2013340. https:\/\/doi.org\/10.3390\/antibiotics3030317 (2014).","journal-title":"Antibiot. (Basel)"},{"key":"11949_CR37","doi-asserted-by":"publisher","unstructured":"Motavaf, B. et al. Detection of genomic mutations in katG and rpoB genes among multidrug-resistant Mycobacterium tuberculosis isolates from Tehran, Iran. New Microbes New Infect.  41 100879. (2021). https:\/\/doi.org\/10.1016\/j.nmni.2021.100879","DOI":"10.1016\/j.nmni.2021.100879"},{"issue":"Suppl 2","key":"11949_CR38","doi-asserted-by":"publisher","first-page":"S228","DOI":"10.1093\/infdis\/jir858","volume":"205","author":"A Zumla","year":"2012","unstructured":"Zumla, A. et al. Drug-resistant tuberculosis\u2013current dilemmas, unanswered questions, challenges, and priority needs. J. Infect. Dis. 205 (Suppl 2), S228\u2013S240. https:\/\/doi.org\/10.1093\/infdis\/jir858 (2012).","journal-title":"J. Infect. Dis."},{"issue":"9","key":"11949_CR39","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.3390\/antibiotics11091215","volume":"11","author":"F Zhang","year":"2022","unstructured":"Zhang, F. & Cheng, W. The mechanism of bacterial resistance and potential bacteriostatic strategies. Antibiot. (Basel). 11 (9), 1215. https:\/\/doi.org\/10.3390\/antibiotics11091215 (2022).","journal-title":"Antibiot. (Basel)"},{"issue":"2","key":"11949_CR40","doi-asserted-by":"publisher","first-page":"521","DOI":"10.4103\/jfmpc.jfmpc_1237_24","volume":"14","author":"S Ravikoti","year":"2025","unstructured":"Ravikoti, S., Bhatia, V. & Mohanasundari, S. K. Recent advancements in tuberculosis (TB) treatment regimens. J. Family Med. Prim. Care. 14 (2), 521\u2013525. https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_1237_24 (2025).","journal-title":"J. Family Med. Prim. Care"},{"issue":"4","key":"11949_CR41","doi-asserted-by":"publisher","first-page":"338","DOI":"10.20529\/IJME.2024.060","volume":"IX","author":"P Anirvan","year":"2024","unstructured":"Anirvan, P. The dire struggle: india\u2019s unfulfilled promise to eliminate tuberculosis. Indian J. Med. Ethics. IX (4), 338\u2013339. https:\/\/doi.org\/10.20529\/IJME.2024.060 (2024).","journal-title":"Indian J. Med. Ethics"},{"issue":"2","key":"11949_CR42","doi-asserted-by":"publisher","first-page":"ofab018","DOI":"10.1093\/ofid\/ofab018","volume":"8","author":"JH Malenfant","year":"2021","unstructured":"Malenfant, J. H. & Brewer, T. F. Rifampicin Mono-Resistant tuberculosis-A review of an uncommon but growing challenge for global tuberculosis control. Open. Forum Infect. Dis. 8 (2), ofab018. https:\/\/doi.org\/10.1093\/ofid\/ofab018 (2021). Published 2021 Jan 28.","journal-title":"Open. Forum Infect. Dis."},{"key":"11949_CR43","doi-asserted-by":"publisher","unstructured":"Dheda, K. et al. Multidrug-resistant tuberculosis. Nat Rev Dis Primers. 10 (1) 22. Published 2024 Mar 24. (2024). https:\/\/doi.org\/10.1038\/s41572-024-00504-2","DOI":"10.1038\/s41572-024-00504-2"},{"key":"11949_CR44","doi-asserted-by":"publisher","first-page":"110817","DOI":"10.1016\/j.cbi.2023.110817","volume":"387","author":"L Malefane","year":"2024","unstructured":"Malefane, L. & Maarman, G. Post-tuberculosis lung disease and inflammatory role players: can we characterise the myriad inflammatory pathways involved to gain a better understanding? Chem. Biol. Interact. 387, 110817. https:\/\/doi.org\/10.1016\/j.cbi.2023.110817 (2024).","journal-title":"Chem. Biol. Interact."},{"issue":"1","key":"11949_CR45","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.tim.2008.09.008","volume":"17","author":"T Ad\u00e9kambi","year":"2009","unstructured":"Ad\u00e9kambi, T., Drancourt, M. & Raoult, D. The RpoB gene as a tool for clinical microbiologists. Trends Microbiol. 17 (1), 37\u201345. https:\/\/doi.org\/10.1016\/j.tim.2008.09.008 (2009).","journal-title":"Trends Microbiol."},{"issue":"8","key":"11949_CR46","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1128\/AEM.67.8.3720-3727.2001","volume":"67","author":"Y Qi","year":"2001","unstructured":"Qi, Y. et al. Utilization of the RpoB gene as a specific chromosomal marker for real-time PCR detection of Bacillus anthracis. Appl. Environ. Microbiol. 67 (8), 3720\u20133727. https:\/\/doi.org\/10.1128\/AEM.67.8.3720-3727.2001 (2001).","journal-title":"Appl. Environ. Microbiol."},{"issue":"5","key":"11949_CR47","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.jiph.2018.04.005","volume":"11","author":"MT Zaw","year":"2018","unstructured":"Zaw, M. T., Emran, N. A. & Lin, Z. Mutations inside rifampicin-resistance determining region of RpoB gene associated with rifampicin-resistance in Mycobacterium tuberculosis. J. Infect. Public. Health. 11 (5), 605\u2013610. https:\/\/doi.org\/10.1016\/j.jiph.2018.04.005 (2018).","journal-title":"J. Infect. Public. Health"},{"issue":"4","key":"11949_CR48","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s42770-020-00356-4","volume":"51","author":"NL Bhembe","year":"2020","unstructured":"Bhembe, N. L. & Green, E. Characterization of mutations in the RpoB gene conferring rifampicin resistance in Mycobacterium tuberculosis complex isolated from lymph nodes of slaughtered cattle from South Africa. Braz J. Microbiol. 51 (4), 1919\u20131927. https:\/\/doi.org\/10.1007\/s42770-020-00356-4 (2020).","journal-title":"Braz J. Microbiol."},{"key":"11949_CR49","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.2147\/IDR.S333433","volume":"14","author":"MC Li","year":"2021","unstructured":"Li, M. C. et al. RpoB mutations and effects on Rifampin resistance in Mycobacterium tuberculosis. Infect. Drug Resist. 14, 4119\u20134128. https:\/\/doi.org\/10.2147\/IDR.S333433 (2021). Published 2021 Oct 5.","journal-title":"Infect. Drug Resist."},{"key":"11949_CR50","doi-asserted-by":"publisher","unstructured":"Portelli, S. et al. Prediction of rifampicin resistance beyond the RRDR using structure-based machine learning approaches. Sci. Rep.  10  (1) 18120. (2020). https:\/\/doi.org\/10.1038\/s41598-020-74648-y","DOI":"10.1038\/s41598-020-74648-y"},{"key":"11949_CR51","doi-asserted-by":"publisher","unstructured":"Chakravorty, S. et al. The New Xpert M.TB\/RIF Ultra: Improving detection of mycobacterium tuberculosis and resistance to Rifampin in an assay suitable for [oint-of-Care testing. mBio.  8 (4) e00812-17. (2017). https:\/\/doi.org\/10.1128\/mBio.00812-17","DOI":"10.1128\/mBio.00812-17"},{"key":"11949_CR52","doi-asserted-by":"publisher","unstructured":"Nandlal, L., Perumal, R. & Naidoo, K. Rapid Molecular Assays for the Diagnosis of Drug-Resistant Tuberculosis [published correction appears in Infect Drug Resist. ;15:6081\u20136084]. Infect Drug Resist. 2022  15 4971\u20134984.https:\/\/doi.org\/10.2147\/IDR.S381643","DOI":"10.2147\/IDR.S381643"},{"key":"11949_CR53","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ijid.2020.03.023","volume":"95","author":"K Chen","year":"2020","unstructured":"Chen, K. et al. Clinical validation of urine-based Xpert\u00ae M.TB\/RIF assay for the diagnosis of urogenital tuberculosis: A systematic review and meta-analysis. Int. J. Infect. Dis. 95, 15\u201321. https:\/\/doi.org\/10.1016\/j.ijid.2020.03.023 (2020).","journal-title":"Int. J. Infect. Dis."},{"key":"11949_CR54","doi-asserted-by":"publisher","unstructured":"Lawn, S. D., Nicol, M. P. & Xpert\u00ae M.TB\/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance [published correction appears in Future Microbiol. ;7(8):1024]. Future Microbiol. 2011 6(9) 1067\u20131082. (2012). https:\/\/doi.org\/10.2217\/fmb.11.84","DOI":"10.2217\/fmb.11.84"},{"issue":"1","key":"11949_CR55","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1186\/s12879-020-05243-9","volume":"20","author":"JV Ershova","year":"2020","unstructured":"Ershova, J. V. et al. Impact of GeneXpert M.TB\/RIF\u00ae on treatment initiation and outcomes of RResistant and RIF-susceptible TB patients in Vladimir TB dispensary, Russia. BMC Infect. Dis. 20 (1), 543. https:\/\/doi.org\/10.1186\/s12879-020-05243-9 (2020).","journal-title":"BMC Infect. Dis."},{"issue":"52","key":"11949_CR56","doi-asserted-by":"publisher","first-page":"995","DOI":"10.46234\/ccdcw2020.266","volume":"2","author":"S Yu","year":"2020","unstructured":"Yu, S., Ma, J. & Jia, Z. Estimating the incidence of Tuberculosis - Shanghai, china, 2025\u20132050. China CDC Wkly. 2 (52), 995\u2013998. https:\/\/doi.org\/10.46234\/ccdcw2020.266 (2020).","journal-title":"China CDC Wkly."},{"key":"11949_CR57","doi-asserted-by":"publisher","first-page":"7707","DOI":"10.2147\/IDR.S394089","volume":"15","author":"Y Ren","year":"2022","unstructured":"Ren, Y. et al. Trends of rifampicin resistance in patients with pulmonary tuberculosis: A longitudinal analysis based on drug resistance screening in Eastern China between 2015 and 2019. Infect. Drug Resist. 15, 7707\u20137717. https:\/\/doi.org\/10.2147\/IDR.S394089 (2022).","journal-title":"Infect. Drug Resist."},{"issue":"10","key":"11949_CR58","doi-asserted-by":"publisher","first-page":"e0258295","DOI":"10.1371\/journal.pone.0258295","volume":"16","author":"G Diriba","year":"2021","unstructured":"Diriba, G. et al. Drug resistance and its risk factors among extrapulmonary tuberculosis in ethiopia: A systematic review and meta-analysis. PLoS One. 16 (10), e0258295. https:\/\/doi.org\/10.1371\/journal.pone.0258295 (2021).","journal-title":"PLoS One"},{"issue":"3","key":"11949_CR59","doi-asserted-by":"publisher","first-page":"2000626","DOI":"10.1183\/13993003.00626-2020","volume":"56","author":"CF McQuaid","year":"2020","unstructured":"McQuaid, C. F., Horton, K. C., Dean, A. S., Knight, G. M. & White, R. G. The risk of multidrug- or rifampicin-resistance in males versus females with tuberculosis. Eur. Respir J. 56 (3), 2000626. https:\/\/doi.org\/10.1183\/13993003.00626-2020 (2020).","journal-title":"Eur. Respir J."},{"issue":"8","key":"11949_CR60","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1007\/s12098-023-04888-z","volume":"91","author":"HS Schaaf","year":"2024","unstructured":"Schaaf, H. S. & Hughes, J. Current treatment of Drug-Resistant tuberculosis in children. Indian J. Pediatr. 91 (8), 806\u2013816. https:\/\/doi.org\/10.1007\/s12098-023-04888-z (2024).","journal-title":"Indian J. Pediatr."},{"issue":"6","key":"11949_CR61","doi-asserted-by":"publisher","first-page":"e2021054663","DOI":"10.1542\/peds.2021-054663","volume":"148","author":"D Nolt","year":"2021","unstructured":"Nolt, D. & Starke, J. R. Tuberculosis infection in children and adolescents: testing and treatment. Pediatrics 148 (6), e2021054663. https:\/\/doi.org\/10.1542\/peds.2021-054663 (2021).","journal-title":"Pediatrics"},{"issue":"1","key":"11949_CR62","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12879-020-4817-2","volume":"20","author":"A Alemu","year":"2020","unstructured":"Alemu, A. et al. Does Xpert\u00ae MTB\/RIF assay give rifampicin resistance results without identified mutation? Review of cases from addis ababa, Ethiopia. BMC Infect. Dis. 20 (1), 87. https:\/\/doi.org\/10.1186\/s12879-020-4817-2 (2020).","journal-title":"BMC Infect. Dis."},{"issue":"Suppl 1","key":"11949_CR63","doi-asserted-by":"publisher","first-page":"S145","DOI":"10.1016\/j.ijmyco.2016.09.007","volume":"5","author":"EA Ochang","year":"2016","unstructured":"Ochang, E. A. et al. Evaluation of rifampicin resistance and 81-bp rifampicin resistant determinant region of RpoB gene mutations of Mycobacterium tuberculosis detected with xpertmtb\/rif in cross river state, Nigeria. Int. J. Mycobacteriol. 5 (Suppl 1), S145\u2013S146. https:\/\/doi.org\/10.1016\/j.ijmyco.2016.09.007 (2016).","journal-title":"Int. J. Mycobacteriol"},{"key":"11949_CR64","doi-asserted-by":"publisher","first-page":"100342","DOI":"10.1016\/j.jctube.2022.100342","volume":"29","author":"CV Sailo","year":"2022","unstructured":"Sailo, C. V. et al. Distribution and frequency of common mutations in RpoB gene of Mycobacterium tuberculosis detected by Xpert MTB\/RIF and identification of residential areas of rifampicin resistant-TB cases: A first retrospective study from mizoram, Northeast India. J. Clin. Tuberc Other Mycobact. Dis. 29, 100342. https:\/\/doi.org\/10.1016\/j.jctube.2022.100342 (2022).","journal-title":"J. Clin. Tuberc Other Mycobact. Dis."},{"issue":"6","key":"11949_CR65","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1093\/jac\/dkq102","volume":"65","author":"L Chen","year":"2010","unstructured":"Chen, L. et al. RpoB gene mutation profile in rifampicin-resistant Mycobacterium tuberculosis clinical isolates from guizhou, one of the highest incidence rate regions in China. J. Antimicrob. Chemother. 65 (6), 1299\u20131301. https:\/\/doi.org\/10.1093\/jac\/dkq102 (2010).","journal-title":"J. Antimicrob. Chemother."},{"key":"11949_CR66","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2147\/IDR.S240408","volume":"13","author":"MKM Uddin","year":"2020","unstructured":"Uddin, M. K. M. et al. Distribution and frequency of RpoB mutations detected by Xpert MTB\/RIF assay among Beijing and Non-Beijing rifampicin resistant Mycobacterium tuberculosis isolates in Bangladesh. Infect. Drug Resist. 13, 789\u2013797 (2020).","journal-title":"Infect. Drug Resist."},{"issue":"3","key":"11949_CR67","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.1016\/s2666-5247(20)30195-6","volume":"2","author":"Y Ektefaie","year":"2021","unstructured":"Ektefaie, Y., Dixit, A., Freschi, L. & Farhat, M. R. Globally diverse Mycobacterium tuberculosis resistance acquisition: a retrospective geographical and Temporal analysis of whole genome sequences. Lancet Microbe. 2 (3), e96\u2013e104. https:\/\/doi.org\/10.1016\/s2666-5247(20)30195-6 (2021).","journal-title":"Lancet Microbe"},{"key":"11949_CR68","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1186\/s12879-016-1745-2","volume":"16","author":"I Ullah","year":"2016","unstructured":"Ullah, I. et al. Rifampicin resistance mutations in the 81\u00a0bp RRDR of RpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert MTB\/RIF in Khyber pakhtunkhwa, pakistan: a retrospective study. BMC Infect. Dis. 16, 413. https:\/\/doi.org\/10.1186\/s12879-016-1745-2 (2016).","journal-title":"BMC Infect. Dis."},{"key":"11949_CR69","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1186\/1471-2334-14-481","volume":"14","author":"G Mboowa","year":"2014","unstructured":"Mboowa, G., Namaganda, C. & Ssengooba, W. Rifampicin resistance mutations in the 81\u00a0bp RRDR of RpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert\u00ae MTB\/RIF in kampala, uganda: a retrospective study. BMC Infect. Dis. 14, 481. https:\/\/doi.org\/10.1186\/1471-2334-14-481 (2014).","journal-title":"BMC Infect. Dis."},{"key":"11949_CR70","unstructured":"Munir, M. K. et al. Comparison of genexpert\u00ae probe missing in hotspot RRDR of RPOB gene among primary and acquired drug resistant cases of pulmonary tuberculosis.Biol. Clin. Sci. Res. J., 2022: 165. https:\/\/doi.org\/10.54112\/bcsrj.v2022i1.165] 2., Does Xpert\u00ae MTB\/RIF assay give rifampicin resistance results without identified mutation? Review of cases from Addis Ababa, Ethiopia. BMC Infect Dis. 2020 20(1):87. 10.1186\/s12879-020-4817-2 (2022)."},{"issue":"9","key":"11949_CR71","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41579-019-0214-5","volume":"17","author":"CJ Meehan","year":"2019","unstructured":"Meehan, C. J. et al. Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issues. Nat. Rev. Microbiol. 17 (9), 533\u2013545. https:\/\/doi.org\/10.1038\/s41579-019-0214-5 (2019).","journal-title":"Nat. Rev. Microbiol."},{"key":"11949_CR72","doi-asserted-by":"publisher","unstructured":"Sinha, P., Srivastava, G. N., Tripathi, R., Mishra, M. N. & Anupurba, S. Detection of mutations in the rpoB gene of rifampicin-resistant Mycobacterium tuberculosis strains inhibiting wild type probe hybridization in the MTBDR plus assay by DNA sequencing directly from clinical specimens. BMC Microbiol. 20 (1):284. (2020). https:\/\/doi.org\/10.1186\/s12866-020-01967-5","DOI":"10.1186\/s12866-020-01967-5"},{"key":"11949_CR73","doi-asserted-by":"publisher","first-page":"100245","DOI":"10.1016\/j.jctube.2021.100245","volume":"24","author":"FA Gopie","year":"2021","unstructured":"Gopie, F. A. et al. Should treatment of low-level mono-resistant tuberculosis be different? [published correction appears in. J. Clin. Tuberc Other Mycobact. Dis. 24, 100245 (2021). 100245 J. Clin. Tuberc. Other Mycobact. Dis.","journal-title":"J. Clin. Tuberc Other Mycobact. Dis."},{"issue":"8","key":"11949_CR74","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.3390\/pathogens12081015","volume":"12","author":"AN Traor\u00e9","year":"2023","unstructured":"Traor\u00e9, A. N. et al. Isoniazid and rifampicin Resistance-Conferring mutations in Mycobacterium tuberculosis isolates from South Africa. Pathogens 12 (8), 1015. https:\/\/doi.org\/10.3390\/pathogens12081015 (2023). Published 2023 Aug 4.","journal-title":"Pathogens"},{"issue":"9\u201310","key":"11949_CR75","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s00335-017-9713-8","volume":"28","author":"AE Vinogradov","year":"2017","unstructured":"Vinogradov, A. E. & Anatskaya, O. V. DNA helix: the importance of being AT-rich. Mamm. Genome. 28 (9\u201310), 455\u2013464. https:\/\/doi.org\/10.1007\/s00335-017-9713-8 (2017).","journal-title":"Mamm. Genome"},{"issue":"3","key":"11949_CR76","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1089\/mdr.2014.0075","volume":"21","author":"P Mohajeri","year":"2015","unstructured":"Mohajeri, P., Sadri, H., Farahani, A., Norozi, B. & Atashi, S. Frequency of mutations associated with rifampicin resistance in Mycobacterium tuberculosis strains isolated from patients in West of Iran. Microb. Drug Resist. 21 (3), 315\u2013319. https:\/\/doi.org\/10.1089\/mdr.2014.0075 (2015).","journal-title":"Microb. Drug Resist."},{"issue":"3","key":"11949_CR77","doi-asserted-by":"publisher","first-page":"e0238898","DOI":"10.1371\/journal.pone.0238898","volume":"16","author":"S Ameke","year":"2021","unstructured":"Ameke, S. et al. Molecular epidemiology of Mycobacterium tuberculosis complex in the Volta region of Ghana. PLoS One. 16 (3), e0238898. https:\/\/doi.org\/10.1371\/journal.pone.0238898 (2021). Published 2021 Mar 17.","journal-title":"PLoS One"},{"issue":"4","key":"11949_CR78","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.12669\/pjms.37.4.3875","volume":"37","author":"M Alamgir","year":"2021","unstructured":"Alamgir, M., Sajjad, M., Baig, M. S. & Noori, M. Y. Mutational frequencies in mycobacterial RpoB gene using genexpert\/mtb Rif assay in rifampicin resistant patients at a tertiary care setting in urban sindh, pakistan: analysis from a Five-Year period. Pak J. Med. Sci. 37 (4), 1151\u20131154. https:\/\/doi.org\/10.12669\/pjms.37.4.3875 (2021).","journal-title":"Pak J. Med. Sci."},{"issue":"1","key":"11949_CR79","doi-asserted-by":"publisher","first-page":"e0262929","DOI":"10.1371\/journal.pone.0262929","volume":"17","author":"W Admassu","year":"2022","unstructured":"Admassu, W., Ayelign, B., Abebe, G. & Tadesse, M. Detection of Mycobacterium tuberculosis and rifampicin resistance by Xpert\u00ae MTB\/RIF assay among presumptive tuberculosis cases at Jimma university medical center, Southwest Ethiopia. PLoS One. 17 (1), e0262929. https:\/\/doi.org\/10.1371\/journal.pone.0262929 (2022). Published 2022 Jan 27.","journal-title":"PLoS One"},{"key":"11949_CR80","doi-asserted-by":"publisher","first-page":"101574","DOI":"10.1016\/j.cimid.2020.101574","volume":"74","author":"JL Khawbung","year":"2021","unstructured":"Khawbung, J. L., Nath, D. & Chakraborty, S. Drug resistant tuberculosis: A review. Comp. Immunol. Microbiol. Infect. Dis. 74, 101574. https:\/\/doi.org\/10.1016\/j.cimid.2020.101574 (2021).","journal-title":"Comp. Immunol. Microbiol. Infect. Dis."},{"key":"11949_CR81","doi-asserted-by":"publisher","unstructured":"Jones, R. M., Adams, K. N., Eldesouky, H. E. & Sherman, D. R. The evolving biology of Mycobacterium tuberculosis drug resistance. Front Cell Infect Microbiol. ;12:1027394. Published 2022 Oct 5. (2022). https:\/\/doi.org\/10.3389\/fcimb.2022.1027394","DOI":"10.3389\/fcimb.2022.1027394"},{"issue":"6","key":"11949_CR82","doi-asserted-by":"publisher","first-page":"e0270003","DOI":"10.1371\/journal.pone.0270003","volume":"17","author":"Y Xi","year":"2022","unstructured":"Xi, Y., Zhang, W., Qiao, R. J. & Tang, J. Risk factors for multidrug-resistant tuberculosis: A worldwide systematic review and meta-analysis. PLoS One. 17 (6), e0270003. https:\/\/doi.org\/10.1371\/journal.pone.0270003 (2022). Published 2022 Jun 16.","journal-title":"PLoS One"},{"key":"11949_CR83","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.2147\/IDR.S333433","volume":"14","author":"MC Li","year":"2021","unstructured":"Li, M. C. et al. RpoB mutations and effects on Rifampin resistance in Mycobacterium tuberculosis. Infect. Drug Resist. 14, 4119\u20134128. https:\/\/doi.org\/10.2147\/IDR.S333433 (2021). Published 2021 Oct 5.","journal-title":"Infect. Drug Resist."},{"issue":"6","key":"11949_CR84","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1128\/JCM.00691-14","volume":"52","author":"FB Jamieson","year":"2014","unstructured":"Jamieson, F. B. et al. Profiling of RpoB mutations and mics for Rifampin and Rifabutin in Mycobacterium tuberculosis. J. Clin. Microbiol. 52 (6), 2157\u20132162. https:\/\/doi.org\/10.1128\/JCM.00691-14 (2014).","journal-title":"J. Clin. Microbiol."},{"key":"11949_CR85","doi-asserted-by":"publisher","first-page":"6853","DOI":"10.2147\/IDR.S386863","volume":"15","author":"MC Li","year":"2022","unstructured":"Li, M. C. et al. RpoB mutations are associated with variable levels of Rifampin and Rifabutin resistance in Mycobacterium tuberculosis. Infect. Drug Resist. 15, 6853\u20136861. https:\/\/doi.org\/10.2147\/IDR.S386863 (2022). Published 2022 Nov 28.","journal-title":"Infect. Drug Resist."},{"issue":"2","key":"11949_CR86","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1128\/AAC.01024-12","volume":"57","author":"Y Pang","year":"2013","unstructured":"Pang, Y. et al. Study of the Rifampin monoresistance mechanism in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 57 (2), 893\u2013900. https:\/\/doi.org\/10.1128\/AAC.01024-12 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"11949_CR87","doi-asserted-by":"publisher","first-page":"968","DOI":"10.3390\/vaccines11050968","volume":"11","author":"Y He","year":"2023","unstructured":"He, Y. et al. Clinical characteristics of mild patients with breakthrough infection of Omicron variant in China after relaxing the dynamic zero COVID-19 policy. Vaccines (Basel). 11 (5), 968. https:\/\/doi.org\/10.3390\/vaccines11050968 (2023). Published 2023 May 10.","journal-title":"Vaccines (Basel)"},{"key":"11949_CR88","doi-asserted-by":"publisher","first-page":"e84790","DOI":"10.7554\/eLife.84790","volume":"12","author":"NS Brunetti","year":"2023","unstructured":"Brunetti, N. S. et al. SARS-CoV-2 uses CD4 to infect T helper lymphocytes. Elife 12, e84790. https:\/\/doi.org\/10.7554\/eLife.84790 (2023). Published 2023 Jul 31.","journal-title":"Elife"},{"issue":"6","key":"11949_CR89","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1177\/87551225221116266","volume":"38","author":"EJ Koshi","year":"2022","unstructured":"Koshi, E. J., Young, K., Mostales, J. C., Vo, K. B. & Burgess, L. P. Complications of corticosteroid therapy: A comprehensive literature review. J. Pharm. Technol. 38 (6), 360\u2013367. https:\/\/doi.org\/10.1177\/87551225221116266 (2022).","journal-title":"J. Pharm. Technol."},{"key":"11949_CR90","doi-asserted-by":"publisher","DOI":"10.1590\/0034-7167-2022-0803","author":"BPMD Silva","year":"2023","unstructured":"Silva, B. P. M. D. et al. Drug-Resistant Tuberculosis and COVID-19: A scoping review on a new threat to antimicrobial resistance. Rev. Bras. Enferm. 76 (Suppl 1), e20220803. https:\/\/doi.org\/10.1590\/0034-7167-2022-0803 (2023)."},{"key":"11949_CR91","doi-asserted-by":"publisher","first-page":"747827","DOI":"10.3389\/fmicb.2021.747827","volume":"12","author":"N Bostanghadiri","year":"2022","unstructured":"Bostanghadiri, N., Jazi, F. M., Razavi, S., Fattorini, L. & Darban-Sarokhalil, D. Mycobacterium tuberculosis and SARS-CoV-2 coinfections: A review. Front. Microbiol. 12, 747827. https:\/\/doi.org\/10.3389\/fmicb.2021.747827 (2022). Published 2022 Feb 3.","journal-title":"Front. Microbiol."},{"key":"11949_CR92","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jmgm.2016.04.005","volume":"67","author":"A Nusrath Unissa","year":"2016","unstructured":"Nusrath Unissa, A., Hassan, S., Indira Kumari, V., Revathy, R. & Hanna, L. E. Insights into RpoB clinical mutants in mediating rifampicin resistance in Mycobacterium tuberculosis. J. Mol. Graph Model. 67, 20\u201332. https:\/\/doi.org\/10.1016\/j.jmgm.2016.04.005 (2016).","journal-title":"J. Mol. Graph Model."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-11949-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-11949-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-11949-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T09:32:05Z","timestamp":1757323925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-11949-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":92,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11949"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-11949-0","relation":{"references":[{"id-type":"doi","id":"10.1590\/0034-7167-2022-0803","asserted-by":"subject"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"assertion":[{"value":"18 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethical approval was waived by the local Ethics Committee of Jiangxi Province Chest Hospital in view of the retrospective nature of the study and all the procedures had been performed were part of the routine care.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}}],"article-number":"27988"}}